Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Blood (2014) 124 (21): 621.

https://doi.org/10.1182/blood.V124.21.621.621

Published: 2014

Journal Articles

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

Blood (2014) 124 (21): 10.

https://doi.org/10.1182/blood.V124.21.10.10

Published: 2014

Journal Articles

Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)

Guillermo Garcia -Manero, MD, Michael Savona, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Paul Conkling, MD, CL Beach, PharmD, Joel Hetzer, PhD, Qian Dong, MS, Barry S. Skikne, MD

Blood (2013) 122 (21): 1554.

https://doi.org/10.1182/blood.V122.21.1554.1554

Published: 2013

Journal Articles

Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine,

Tao Shi, PhD, Ludmila Danilova, PhD, Xiaolong Luo, PhD, Lela M. Lucy, MS, CL Beach, PharmD, Leslie Cope, PhD, James G. Herman, MD, Kyle J. MacBeth, PhD

Blood (2011) 118 (21): 3815.

https://doi.org/10.1182/blood.V118.21.3815.3815

Published: 2011

Journal Articles

A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment,

Eric Laille, MS, Alain C. Mita, MD, Sanjay Goel, MD, MS, Nashat Y. Gabrail, MD, Joseph Schwarz, MBA, CL Beach, PharmD

Blood (2011) 118 (21): 3480.

https://doi.org/10.1182/blood.V118.21.3480.3480

Published: 2011

Journal Articles

Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA)

Raphael Itzykson, Sylvain Thepot, Odile Beyne-Rauzy, Bruno Quesnel, Shanti Ame, MD, Pascal Turlure, Stephanie Harel, Anne Marfaing-Koka, Youcef Chelgoum, Aspasia Stamatoullas, Madalina Uzunov, Norbert Ifrah, Herve Dombret, MD, PhD, Lionel Ades, CL Beach, PharmD, Arlene S. Swern, PhD, Claude Gardin, Pierre Fenaux

Blood (2010) 116 (21): 2183.

https://doi.org/10.1182/blood.V116.21.2183.2183

Published: 2010

Journal Articles

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

John F Seymour, MD, FRACP, Valeria Santini, MD, Pierre Fenaux, MD, Aristoteles A.N. Giagounidis, MD, Guillermo F. Sanz, MD, PhD, Carlo Finelli, MD, Lela M. Lucy, MS, Jay Backstrom, MD, MPH, CL Beach, PharmD

Blood (2010) 116 (21): 1856.

https://doi.org/10.1182/blood.V116.21.1856.1856

Published: 2010

Journal Articles

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Blood (2010) 116 (21): 3996.

https://doi.org/10.1182/blood.V116.21.3996.3996

Published: 2010

Journal Articles

Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk

Norbert Gattermann, MD, Guillermo F. Sanz, MD, PhD, Aristoteles Giagounidis, John F Seymour, MD, FRACP, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Ghulam J. Mufti, DM, FRCP, FRCPath, Petra Muus, MD, PhD, Fernando Ramos, MD, Lela M. Lucy, MS, CL Beach, PharmD, Lewis R. Silverman, MD

Blood (2010) 116 (21): 4031.

https://doi.org/10.1182/blood.V116.21.4031.4031

Published: 2010

Journal Articles

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Steven D. Gore, MD, Valeria Santini, MD, Pierre Fenaux, MD, PhD, Lewis R. Silverman, MD, Anne Hagemeijer, MD, Barry Skikne, MD, Eva Hellstrom-Lindberg, MD, PhD, John F. Seymour, MBBS, PhD, FRACP, CL Beach, PharmD, Jay Backstrom, MD, MPH, Indrasiri Fernando, PhD

Blood (2009) 114 (22): 1755.

https://doi.org/10.1182/blood.V114.22.1755.1755

Published: 2009

NARROW

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)

Identification of a DNA Methylation Predictive Signature of Overall Survival in Higher-Risk MDS Patients Treated with Azacitidine,

A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment,

Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA)

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only